Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Change in Acquisitions & Divestments (2022 - 2025)

Treace Medical Concepts (TMCI) has disclosed Change in Acquisitions & Divestments for 4 consecutive years, with $17.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Acquisitions & Divestments fell 29.53% year-over-year to $17.7 million, compared with a TTM value of $67.3 million through Dec 2025, down 43.2%, and an annual FY2025 reading of $67.3 million, down 43.2% over the prior year.
  • Change in Acquisitions & Divestments was $17.7 million for Q4 2025 at Treace Medical Concepts, up from $16.2 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $37.0 million in Q4 2023 and bottomed at $1.7 million in Q4 2022.
  • Average Change in Acquisitions & Divestments over 4 years is $23.7 million, with a median of $24.2 million recorded in 2024.
  • The sharpest move saw Change in Acquisitions & Divestments skyrocketed 2042.57% in 2023, then tumbled 54.01% in 2025.
  • Year by year, Change in Acquisitions & Divestments stood at $1.7 million in 2022, then surged by 2042.57% to $37.0 million in 2023, then plummeted by 32.02% to $25.2 million in 2024, then dropped by 29.53% to $17.7 million in 2025.
  • Business Quant data shows Change in Acquisitions & Divestments for TMCI at $17.7 million in Q4 2025, $16.2 million in Q3 2025, and $16.7 million in Q2 2025.